StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for GOVX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $1.33 | $1.23 | -7.52% | 0.3M |
| 05-18 | $3.03 | $2.21 | -27.06% | 208.9M |
| 05-19 | $1.95 | $2.01 | +3.08% | 6.7M |
| 05-20 | $1.96 | $2.23 | +13.78% | 4.6M |
| 05-21 | $2.18 | $2.75 | +26.15% | 11.1M |
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $2.49M | $2.49M | $2.49M |
Operating Income | $-5.27M | $-21.64M | $-17.20M | $-10.82M |
Net Income | $-5.26M | $-21.46M | $-17.05M | $-5.37M |
EPS (Diluted) | $-2.62 | $-22.40 | $-0.97 | $-0.79 |
Total Assets | $2.98M | $6.34M | $6.73M | $5.35M |
Total Liabilities | $2.49M | $2.52M | Not available | Not available |
Cash & Equivalents | $1.27M | $3.09M | $5.01M | $3.09M |
Free Cash Flow OCF − CapEx | $-3.54M | $-21.50M | $-16.54M | $-10.33M |
Shares Outstanding | 2.82M | 1.73M | 29.71M | 15.92M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.